Board Meeting On November 13, 2017.
We wish to inform that a meeting of Board of Directors will be held on Monday, the 13th day of November, 2017 inter alia to consider the Un-audited Financial Results for the Second Quarter ended 30th September, 2017 in compliance of Regulation 33 of the SEBI (LODR) Regulations, 2015. It is further intimated that Trading Window would remain closed from 06/11/2017 to... Compliance Certificate For The Half Year Ended 30Th September, 2017
With reference to subject cited above, we herewith forward the compliance certificate issued under regulation 40(9) of SEBI (LODR) Regulations, 2015. Compliance Certificate For The Period Ended 30Th September, 2017.
With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015, issued by the Company and the RTA i.e. M/s. Karvy Computershare Private Limited Resignation of Chief Financial Officer (CFO)
We hereby intimate you that Mr. Rajendra Dugar, Chief Financial Officer (CFO) will cease to be CFO w.e.f 31st October, 2017. Statement Of Investor Complaints/Grievances For The Quarter Ended 30Th September, 2017.
In Compliance with the requirement under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find the statement of investor Complaints/Grievances for the quarter ended 30th September, 2017. Shareholding for the Period Ended September 30, 2017
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramakant Inani Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vishnukant Bhutada Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepak Kumar Inani Updates
This is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for the Company's generic pharmaceutical manufacturing facility at Jadcherla in Telangana, India which was inspected between 24th and 28th July 2017. The inspection has now been closed by the US FDA. The Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued...